IBIO, INC. Deferred Revenue Recognized
IBIO, INC. (IBIO) reported Deferred Revenue Recognized of $50.00 thousand for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-28.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2026-08-28
- IBIO, INC. contract with customer, liability, revenue recognized for the quarter ending 2026-03-31 was $0.00.
- IBIO, INC. contract with customer, liability, revenue recognized for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- IBIO, INC. contract with customer, liability, revenue recognized for the quarter ending 2025-03-31 was $0.00.
- IBIO, INC. contract with customer, liability, revenue recognized for the quarter ending 2024-12-31 was $200.00K.
- IBIO, INC. contract with customer, liability, revenue recognized for fiscal 2026 was $50.00K, a 75.00% decline from fiscal 2025.
- IBIO, INC. contract with customer, liability, revenue recognized for fiscal 2025 was $200.00K.
- IBIO, INC. contract with customer, liability, revenue recognized for fiscal 2023 was $100.00, a 99.94% decline from fiscal 2022.
- IBIO, INC. contract with customer, liability, revenue recognized for fiscal 2022 was $178.00K, a 83.62% decline from fiscal 2021.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 3 month as first filed | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 9 month as first filed | Contract with Customer, Liability, Revenue Recognized 12 month | Contract with Customer, Liability, Revenue Recognized 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $50.00K 10-K · filed 2026-08-28 | ||||||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-12 | $50.00K 10-Q · filed 2026-05-12 | |||||
| 2025-12-31 | $0.00 10-Q · filed 2026-02-10 | $50.00K 10-Q · filed 2026-02-10 | |||||
| 2025-06-30 | $200.00K 10-K · filed 2026-08-28 | $50.00K 10-Q · filed 2025-11-12 | |||||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-12 | $200.00K 10-Q · filed 2026-05-12 | |||||
| 2024-12-31 | $200.00K 10-Q · filed 2026-02-10 | $200.00K 10-Q · filed 2026-02-10 | |||||
| 2024-09-30 | $0.00 10-Q/A · filed 2025-11-17 | ||||||
| 2023-06-30 | $100.00 10-K · filed 2023-09-27 | ||||||
| 2022-09-30 | $56.00K 10-Q · filed 2023-11-14 | ||||||
| 2022-06-30 | $178.00K 10-K · filed 2023-09-27 | ||||||
| 2022-03-31 | $52.00K 10-Q · filed 2022-05-12 | $178.00K 10-Q · filed 2022-05-12 | |||||
| 2021-12-31 | $42.00K 10-Q · filed 2022-02-14 | $126.00K 10-Q · filed 2022-02-14 | |||||
| 2021-09-30 | $84.00K 10-Q · filed 2022-11-14 | ||||||
| 2021-06-30 | $1.09M 10-K · filed 2022-10-11 | ||||||
| 2021-03-31 | $388.00K 10-Q · filed 2022-05-12 | $887.00K 10-Q · filed 2022-05-12 | |||||
| 2020-12-31 | $187.00K 10-Q · filed 2022-02-14 | $499.00K 10-Q · filed 2022-02-14 | |||||
| 2020-09-30 | $311.80K 10-Q · filed 2021-11-15 | ||||||
| 2020-06-30 | $1.09M 10-K · filed 2021-09-28 | $1.28M 10-K · filed 2020-10-13 | |||||
| 2020-03-31 | $86.00K 10-Q · filed 2021-05-17 | $75.00K 10-Q · filed 2020-05-15 | $204.00K 10-Q · filed 2021-05-17 | $193.00K 10-Q · filed 2020-05-15 | |||
| 2019-12-31 | $25.00K 10-Q · filed 2021-02-16 | $118.00K 10-Q · filed 2021-02-16 | |||||
| 2019-09-30 | $93.00K 10-Q · filed 2020-11-16 | $47.20K 10-Q · filed 2019-11-14 | |||||
| 2019-06-30 | $1.28M 10-K · filed 2020-10-13 | $2.90M 10-K · filed 2019-08-26 | |||||
| 2019-03-31 | $2.90M 10-Q · filed 2019-05-10 | ||||||
| 2018-12-31 | $1.40M 10-Q · filed 2019-02-13 | $2.90M 10-Q · filed 2019-02-13 | |||||
| 2018-09-30 | $3.10M 10-K · filed 2020-10-13 | $2.90M 10-Q · filed 2018-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |